July 16, 2024
photodynamic therapy

New Photodynamic Therapy Approach Shows Promise in Eliminating Ocular Melanoma: Study

A recent study published in the journal “Nature Communications” sheds light on a novel photodynamic therapy (PDT) method that holds potential in eradicating ocular melanoma, a type of eye cancer.

Researchers at the University of California, Los Angeles (UCLA) have discovered a new approach to PDT that utilizes a combination of two photosensitizing agents, making the treatment more effective and potentially eliminating the need for repeat treatments.

The team, led by Dr. Michael J. Grunwald, used a mouse model to test the new PDT method. They found that the combination of the two agents, when activated by specific wavelengths of light, was able to destroy ocular melanoma cells more efficiently than previous PDT methods.

The researchers believe that this new approach could lead to a more effective and less invasive treatment for ocular melanoma, which currently has limited treatment options. The study also suggests that the new PDT method could potentially eliminate the need for repeat treatments, which are often necessary with current methods.

PDT is a non-invasive treatment that uses a photosensitizing agent and light to destroy cancer cells. The treatment has been used to treat various types of cancer, including ocular melanoma, but the current methods have limitations and require multiple treatments.

The new PDT method, which uses a combination of two photosensitizing agents, could change the way ocular melanoma is treated. The researchers are now planning clinical trials to test the safety and efficacy of the new treatment in humans.

The study, “Combination photodynamic therapy using a near-infrared photosensitizer and a visible photosensitizer for the treatment of ocular melanoma,” was published in the journal “Nature Communications” on .

This new PDT method holds great promise in the fight against ocular melanoma and could lead to a more effective and less invasive treatment option for patients. Further research is needed to fully understand the potential of this new approach and to bring it to clinical use.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it